These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3263543)

  • 1. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
    Anderson TD; Hayes TJ; Gately MK; Bontempo JM; Stern LL; Truitt GA
    Lab Invest; 1988 Nov; 59(5):598-612. PubMed ID: 3263543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK; Anderson TD; Hayes TJ
    J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of human recombinant interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement.
    Anderson TD; Hayes TJ
    Lab Invest; 1989 Mar; 60(3):331-46. PubMed ID: 2784516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
    Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
    Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human recombinant interleukin-2 provokes acute pulmonary vascular endothelial injury in rabbits.
    Goldblum SE; Yoneda K; Cibull M; Pearson T; Hall C; Marshall ME
    J Biol Response Mod; 1990 Apr; 9(2):127-39. PubMed ID: 2160520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.
    DeJoy SQ; Jeyaseelan R; Torley LW; Schow SR; Wick MM; Kerwar SS
    Cancer Res; 1995 Nov; 55(21):4929-35. PubMed ID: 7585532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of asialo GM 1 positive cells in the control of metastatic spread of tumor cells in mice].
    Shibuya M; Saijo N; Ozaki A; Beppu Y; Shimizu E; Takizawa T; Hoshi A
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1781-6. PubMed ID: 6882003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer.
    Wiltrout RH; Boyd MR; Back TC; Salup RR; Arthur JA; Hornung RL
    J Immunol; 1988 May; 140(9):3261-5. PubMed ID: 3258894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of liver lymphoid cell subsets pre- and post-in vivo administration of human recombinant interleukin 2 in a C57BL/6 murine system.
    Lafreniere R; Borkenhagen K; Bryant LD; Anton AR; Chung A; Poon MC
    Cancer Res; 1990 Mar; 50(5):1658-66. PubMed ID: 2302721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of large granular T lymphocytes in vivo during viral infection.
    Biron CA; Natuk RJ; Welsh RM
    J Immunol; 1986 Mar; 136(6):2280-6. PubMed ID: 3485144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
    Chan P
    Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.